Stay ahead of developments in federal and state health care law, regulation and transactions with timely, expert news and analysis.
The medical devices industry has seen a rise in the number of FDA approvals and guidance over the past months, and a prominent health-care attorney expects that to continue due to an agency commitment to speed up device approvals.
Faster device approvals by the Food and Drug Administration will benefit both patients and device makers, while creating minimal safety risks, Chad Landmon, an attorney at Axinn, Veltrop & Harkrider LLP’s Hartford, Conn., office, told Bloomberg Law in an early December video interview.
FDA Commissioner Scott Gottlieb told the Senate Health, Education, Labor and Pensions Committee earlier in December that the agency is on track to approve the highest number of novel medical devices in its modern history.
Landmon, chair of Axinn’s FDA practice group, said both Congress and the Trump administration are responsible for the agency’s new approach.
This administration is more focused on getting devices to market quicker than its predecessor, Landmon said. In draft guidance released in mid-December, the FDA set a new tone for the agency to use the most efficient and least burdensome means possible during the device approval process. The guidance appeared to be part of a larger initiative to change how the FDA handles approvals and clearances, and the agency said its goal is to reduce approval times, reduce costs on device makers, and spur innovation. Most devices reach the U.S. market through a clearance process based on similarity to other technologies, but novel and higher-risk devices need premarket approval.
Landmon said the 21st Century Cures Act, which became law in December 2016, is also to thank for the record number of new devices hitting the market.
“A lot of what we’ve seen with the record number of approvals are from things that were put in place prior to the administration,” he said. The Cures Act “really allowed FDA to staff up and get more people reviewing the products, and getting things to market quickly.”
The Cures Act established the FDA’s voluntary Breakthrough Devices Program to help patients more quickly obtain certain devices for life-threatening or debilitating diseases. Under the program, all submissions for breakthrough devices receive priority review and are placed at the top of the appropriate review queue and will receive additional review resources as needed. The FDA released initial draft guidance for the program in October, and in November it approved FoundationOne CDx (F1CDx), the first breakthrough-designated, next-generation sequencing-based in vitro diagnostic test that can detect genetic mutations in tumors.
A patient safety advocacy group has expressed concern that by reducing burdens on device makers, the FDA has prioritized quicker reviews over patient safety, and could be increasing burdens on patients and doctors.
“We all agree that FDA reviews should be as efficient as possible and not require extraneous information,” Diana Zuckerman, president of the National Center for Health Research, a Washington-based nonprofit, told Bloomberg Law. “But FDA’s vision of reducing burdens to promote innovation too often means that new devices get on the market before there is scientific evidence that they are safe and effective in the short term or the long term.”
Landmon said FDA has not watered down its standards and that approval and clearance criteria may actually be getting more difficult.
“All FDA has done is put its focus on having an appropriate number of people there to do the reviews, on speed and communication back to the industry, and having better dialog with applicants in order to speed their products to market,” he said. “I don’t think that’s a real concern we need to worry about.”
The FDA has argued that more device approvals will mean more and better treatments, but Landmon said manufacturers will also see more money. Landmon mentioned that recently approved cancer therapies, as well as a December guidance on 3D printed (or additive manufactured) devicese, will allow for more precise treatments.
“Having medical devices that are actually tailored to patients just has so many benefits in terms of taking a product off the shelf that might fit depending on what you’re using it for,” he said. “Industry is certainly going to benefit from this as well.”
To contact the reporter on this story: Mike Stankiewicz in Washington at firstname.lastname@example.org
To contact the editor responsible for this story: Brian Broderick at email@example.com
The video is at http://src.bna.com/u2X.
Copyright © 2017 The Bureau of National Affairs, Inc. All Rights Reserved.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to firstname.lastname@example.org.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to email@example.com.
Put me on standing order
Notify me when new releases are available (no standing order will be created)